Abstract:Waldenstrom macroglobulinemia (WM) is a rare and incurable B cell malignancy. Most WM cells express CD20, which enables the use of anti-CD20 monoclonal antibody rituximab-based strategies. Rituximab has been evaluated in WM for about 10 years as a single agent with major response rates of 30% to 40%, whereas the combination of rituximab with chemotherapy has resulted in response rates of 70% to 90% [1,2,3]. However, the extent to which achievement of complete response (CR) confers clinical benefit is still debatable. As such, we administered rituximab (375 mg/m2, day 0) combined with fludarabine (40 mg, days 1-3) or cyclophosphamide (200 mg, days 1-2) in WM patients naive to rituximab and report herein the toxicities and effects of these combinations. A total of 4 elderly patients (ages older than 80) were identified with WM diagnoses from 2007 to 2012 in our department. According to recommendations for assessing response from the Third International Workshop on WM, 2 of 4 (50%) patients achieved complete response, 2 (50%) had major or minor response, and the overall response rate was 100% at the end of the treatment [4]. The individual changes in serum IgM, IgM paraprotein, and hemoglobin levels for all patients are shown in Figure 1. Figure 1 Individual changes in A) IgM, B) IgM paraprotein, and C) HB serum levels Hematologic toxicity was one of the major side effects of this regimen. Neutropenia and thrombocytopenia were found in 2 patients at the end of the treatment. Pulmonary infection was observed in one patient. With a median follow-up of 27 months, all 4 patients died. Two patients with sustainable CR died of pulmonary infection or heart failure, respectively, after follow-up for 11 and 36 months. One patient who achieved a major response duration of 34 months died of duodenal squamous adenocarcinoma. The last patient with minor response had progression of disease in 2 months and died of WM after 10 months of follow-up. Gruson et al. assigned a rituximab and fludarabine combination in a treatment cycle that was repeated every month for 6 months. Five patients aged 52-85 years with IgM achieved overall and complete response at 80% and 40%, respectively [5]. Several analyses have identified age as a major adverse factor [6]. Our results showed that 2 patients with sustainable CR were older than 80 years old and had high-risk International Prognostic Scoring System for WM scores. Therefore, with this combination regimen, age is no longer a major risk factor. In a study by Dimopoulos et al., which combined rituximab and fludarabine or cyclophosphamide in 11 patients with WM, combination treatment was used monthly for 4 cycles. The partial response rate was only 55% and no patients achieved complete response [7]. The 4-cycle combination therapy was thus not enough for WM patients and 5-6 cycles were necessary. In conclusion, rituximab in association with fludarabine or cyclophosphamide is well tolerated and effective for elderly WM patients.

Data from Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

In Vitro and in Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome.

Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow

High-Throughput Microrna Profiling in Patients with Waldenstrom’s Macroglobulinemia.

Cancer Therapeutics Insights In Vitro and In Vivo Therapeutic Ef fi cacy of Car fi lzomib in Mantle Cell Lymphoma : Targeting the Immunoproteasome

Targeting the Bone Marrow in Waldenstrom Macroglobulinemia

Treatment with Histone Deacetylase 6-Specific Inhibitor Wt-161 Disrupts Hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal Er Stress Induced by Proteasome Inhibitor Carfilzomib

Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy

Clinical analysis of 15 patients with Waldenstr?m macroglobulinemia received bortezomib-based treatment

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple Myeloma: A Meta-Analysis of Data from Clinical Trials

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells Via Modulation of Ros Generation and Erk1/2

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL‐BRB trial

P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS

Emerging drugs for the treatment of Waldenström macroglobulinemia

High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia

RITUXIMAB VERSUS BORTEZOMIB PLUS CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED SYMPTOMATIC WALDENSTRöM MACROGLOBULINEMIA: A RANDOMIZED CONTROLLED PHASE 3 TRIAL

Current approach to Waldenström Macroglobulinemia

Peripheral Neuropathy in Sézary Syndrome: Coincidence or a Part of the Syndrome?